India can be a global leader in supplying affordable and high quality medicines to the world, and especially to the underdeveloped countries where such medicines do not reach the poor because of their high cost and the monopoly of foreign manufacturers, said a leading entrepreneur.
"India has emerged as the pharmacy of the world," said Yousuf Hamied, chairman of pharmaceutical giant Cipla.
Hamied was speaking here Friday at the special screening of "Fire in the Blood" - a documentary that depicts mass devastation in Africa, Asia and other parts of the global South due to obstruction of low cost anti-retroviral drugs used for the treatment of HIV/AIDS.
The documentary was screened by the ministry of external affairs.
"India is not just contributing to the arena of medicines but also playing a humanitarian role by manufacturing medicines and supplying them at a low cost across the world," he said.
"India is supplying essential medicines to people in all corners of the world. It is a great role towards humanity and also an initiative to curb the monopoly over medicines created by multinational pharma companies," said Hamied.
The 59-minute documentary tells the story of how western pharmaceutical companies and governments blocked access to low cost AIDS drugs for the global South countries in 1996 and afterwards - leading to 10 million deaths.
"The right to live should never be contingent to the ability to pay. Medicines that are required the most should never be sold in a monopoly. It is a very sad part of the story that countries, who need the medicines the most, are the ones who can't afford them because of the high cost and the patent by foreign companies to prevent any other firms from manufacturing the same drugs at a low cost," he said.
"The companies having patent rights for medicines should allow other firms to manufacture the drugs and ask for royalty in return. Drugs manufacturing should never be seen as a money making business, especially when the motive is to save lives," Hamied added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
